相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years
Feng Zhou et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2022)
Is the glucocorticoid receptor a key player in prostate cancer?: A literature review
Minas Sakellakis et al.
MEDICINE (2022)
Neutropenic sepsis rates in patients receiving bleomycin, etoposide and cisplatin chemotherapy using olanzapine and reduced doses of dexamethasone compared to a standard antiemetic regimen
Ernese. Gjafa et al.
BJU INTERNATIONAL (2021)
Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
Zhenyu Yang et al.
BMC CANCER (2021)
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer
Romualdo Barroso-Sousa et al.
ONCOLOGIST (2021)
Corticosteroid switch after progression on abiraterone acetate plus prednisone
Giandomenico Roviello et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Emerging role of glucocorticoid receptor in castration resistant prostate cancer: A potential therapeutic target
Raj Kumar
JOURNAL OF CANCER (2020)
Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes
Nobumichi Tanaka et al.
INTERNATIONAL JOURNAL OF UROLOGY (2019)
Hyperglycemia, Classified with Multiple Biomarkers Simultaneously in Men without Diabetes, and Risk of Fatal Prostate Cancer
Michael T. Marrone et al.
CANCER PREVENTION RESEARCH (2019)
Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy
Napa Parinyanitikul et al.
SUPPORTIVE CARE IN CANCER (2018)
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Martin Puhr et al.
CLINICAL CANCER RESEARCH (2018)
The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside
Jieping Hu et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2017)
Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel
Rae Young Kang et al.
SUPPORTIVE CARE IN CANCER (2017)
The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial
Nobumichi Tanaka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Safe dose reduction of steroid pre-medication for docetaxel in head and neck neoplasm treatment
Nan-Xiang Chen et al.
ACTA OTO-LARYNGOLOGICA (2016)
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer
B. A. Teply et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression
Patrizia Ferroni et al.
ONCOLOGIST (2016)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients
Carmel Jacobs et al.
SUPPORTIVE CARE IN CANCER (2015)
Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy
Ka-Eun Yoo et al.
SUPPORTIVE CARE IN CANCER (2015)
Drug Desensitization in the Management of Hypersensitivity Reactions to Monoclonal Antibodies and Chemotherapy
Veronica Mezzano et al.
BIODRUGS (2014)
Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients
S. Jiralerspong et al.
ANNALS OF ONCOLOGY (2013)
Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer
Catherine Duggan et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
Yi Ling Teo et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol
Ekaterini Syrigou et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2011)
Single premedication dose of dexamethasone 20 mg IV before docetaxel administration
Jyoti D Chouhan et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma
Rachel L. Derr et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Glucose Intolerance During Adjuvant Chemotherapy for Breast Cancer
Tamas Hickish et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases
Ingrid Herr et al.
LANCET ONCOLOGY (2006)
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy
J Vardy et al.
BRITISH JOURNAL OF CANCER (2006)
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
JS McCune et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
